Latest news
Imetelstat in GBM
Several previous reports have established a correlation between telomerase activity and histologic grade of gliomas. Imetelstat is a telomerase antagonist and its method of action is competitive with telomere binding, leading to inhibition of telomerase and progressive telomere shortening. A recent paper in Clinical Cancer Research presented results from a study which investigated the effects of imetelstat on primary GBM tumour-initiating cells....
BNOS 2010 at the University of Glasgow, June 23rd - June 25th
This Conference will take place in Glasgow. If you are interested in finding out more, than please go to http://www.gla.ac.uk/cvso/bnos2010/, or download the PDF File.
Somatic mutations of PARK2 in glioblastoma
In a recently published paper in Nature Genetics a group of researchers from Memorial Sloan Kettering Cancer Center and the University of California identified the PARK2 gene as a tumour suppressor on chromosome 6q25.2-q27.
Observations from the 2009 SNO & AANS Meeting, New Orleans USA 2009
Mrs. Kathy Oliver from the IBTA has kindly accepted to share with EANO her observations fo the SNO & AANS Meeting.
This summary of miscellaneous items from the scientific sessions at the SNO/AANS-CNS Section on Tumors conference is based on the writer’s notes and the abstracts of the presentations and posters which appear in “Neuro-Oncology” the official journal of the Society for Neuro-Oncology, Volume 11, Issue 5, October 2009. The abstracts in their entirety are available online on a pay-per-article or payper-issue basis here: http://neuro-oncology.dukejournals.org/cgi/content/full/11/5/563
2-hydroxyglutarate implicated in formation and progression of gliomas
A forthcoming paper in Nature describes how IDH1 mutations result in production of R9-)-2-hydroxyglutarate (2HG), and indicate that the excess of 2HG which accumulates in vivo contributes to the formation and malignant progression of gliomas.
1 [2] [3] [4] [5] [6] [7] [8]
|